Company profile
Vaxcyte, Inc.
NASDAQ:PCVXBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07365826 | phase3 | active_not_recruiting | 2026-01-12 | 2027-03-01 | Vaxcyte, Inc. | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age |
| NCT06720038 | phase2 | active_not_recruiting | 2024-11-25 | 2027-12-01 | Vaxcyte, Inc. | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants |
| NCT07616934 | phase1 | recruiting | 2026-06-01 | 2027-12-01 | Vaxcyte, Inc. | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults |
| NCT05266456 | phase1_2 | completed | 2022-02-22 | 2023-01-10 | Vaxcyte, Inc. | Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults |
| NCT05297578 | phase2 | completed | 2022-06-15 | 2023-02-15 | Vaxcyte, Inc. | Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults |
FDA applications (0)
No records yet.